# A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers

> **NCT03568578** · NA · UNKNOWN · sponsor: **Peking University First Hospital** · enrollment: 450 (estimated)

## Conditions studied

- Hepatitis B
- Liver Fibrosis

## Interventions

- **DRUG:** Entecavir 0.5 mg
- **DRUG:** Anluohuaxian Pill 12g

## Key facts

- **NCT ID:** NCT03568578
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-28
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-09-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568578, "A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03568578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*